Celltrion Receives EC Approval for Avtozma (CT-P47), a Biosimilar to RoActemra (tocilizumab)
Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab) is approved by the European…
FDA Approves Samsung Bioepis OSPOMYV, XBRYK (denosumab-dssb), a Biosimilar to Prolia and Xgeva
OSPOMYV™ and XBRYK™ approved by the U.S. Food and Drug Administration (FDA)…
Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE, XBRYK)
OBODENCE™ and XBRYK™ approved by the European Commission (EC) for all indications…
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely…
AEON Biopharma, Inc. Announces Launch of Proposed Public Offering
January 03, 2025 20:02 ET | Source: AEON Biopharma IRVINE, Calif., Jan.…